Connect with us

Press Release

Securities Clearing Center Company (Muqassa) annonce la date de commencement des opérations

Published

on

La chambre de compensation indépendante (Muqassa) renforcera l’infrastructure du marché des capitaux saoudien et améliorera l’efficacité opérationnelle

RIYAD, Arabie saoudite, 15 juillet 2020 /PRNewswire/ — Securities Clearing Center Company (Société du centre de compensation des valeurs mobilières, Muqassa) a annoncé aujourd’hui qu’elle débutera ses activités le 30/08/2020, correspondant au 11/01/1442H. Après les annonces de sa création en 2018 et de sa licence plus tôt cette année, Muqassa vise à soutenir davantage la croissance du marché des capitaux saoudien en améliorant l’infrastructure post-négociation, à contribuer à réduire le risque de contrepartie, à accroître l’efficacité opérationnelle et à permettre l’introduction de nouveaux produits financiers et offres de services.

L’établissement de Muqassa est l’une des initiatives du Financial Sector Development Program (FSDP), dans le cadre de la Vision 2030 du Royaume, qui soutient également le début de la négociation de produits dérivés sur Tadawul. Le service de compensation débutera avec les produits dérivés négociés en bourse, en compensant le contrat à terme à indice MT30 le 30/08/2020 correspondant au 11/01/1442H, avec d’autres marchés à suivre à un stade ultérieur.

Wael Abdullah Al Hazzani, CEO de Muqassa, a déclaré : « L’activation d’une chambre de compensation indépendante fait partie du Financial Sector Development Program conformément aux objectifs de la Vision 2030 consistant à développer un secteur financier diversifié et efficace dans le Royaume. Nous sommes convaincus que Muqassa améliorera l’infrastructure actuelle des marchés financiers en appliquant des pratiques avancées de gestion des risques et des processus transparents de gestion par défaut. »

Le lancement des opérations de Muqassa est facilité par les efforts déployés par Tadawul, Muqassa, la Capital Market Authority (CMA) et la Saudi Arabian Monitory Authority (SAMA) pour s’assurer que les lois et réglementations requises pour l’activation de la chambre de compensation soient en place. La loi récemment modifiée sur les marchés des capitaux (Capital Market Law), les réglementations sur les contreparties centrales des valeurs mobilières (Securities Central Counterparties Regulations) et les règles et procédures du centre de compensation des valeurs mobilières (Securities Clearing Center Rules and Procedures) aideront à réglementer le centre de compensation des valeurs mobilières et à activer son rôle dans l’exécution de ses devoirs et obligations au sein des institutions d’infrastructure des marchés de capitaux.

À propos de Tadawul

La bourse saoudienne (Tadawul) est la seule entité autorisée au Royaume d’Arabie saoudite à agir en tant que bourse de valeurs du Royaume (la Bourse), cotant et négociant des titres. Le marché boursier saoudien est le 9e plus grand marché boursier parmi les 67 membres de la Fédération mondiale des bourses et est le marché dominant du Conseil de coopération du Golfe (CCG). La Bourse est le 3e plus grand marché boursier parmi ses pairs des marchés émergents.

Pour tout complément d’information, veuillez consulter le site : www.tadawul.com.sa.

À propos de Securities Clearing Center Company (Muqassa)

Securities Clearing Center Company « Muqassa » a été fondée en 2018 en tant que société par actions fermée entièrement détenue par la Bourse saoudienne (Tadawul).

L’établissement et l’exploitation de Muqassa est l’une des initiatives du Financial Sector Development Program 2020 (FSDP), dans le cadre de la Vision 2030 du Royaume.

Muqassa contribuera à réduire les risques post-négociation, fournira une gestion centralisée des risques des contreparties et développera des services de compensation conformément aux meilleures pratiques internationales de gestion des risques afin de s’aligner sur les marchés financiers mondiaux avancés, ce qui attirera les investisseurs sur le marché.

www.muqassa.sa 

Contact chez Tadawul :
Mohammed Al Abdullah
+966-(54)-541-1133
[email protected]

Contact chez Finsbury :
Ahmed Jebur
+971-(52)-290-3518
[email protected]

Logo : https://mma.prnewswire.com/media/1214165/Muqassa_Logo.jpg
SOURCE Muqassa

This story has been sourced from a third party syndicated feed, agencies. News Galiyara accepts no responsibility or liability for its dependability, trustworthiness, reliability, and data of the text. DigitalGaliyara (OPC) Private Limited management reserves the sole right to alter, delete or remove (without notice). If you have any concerns with the Content, then please write to us at the mail@digitalgaliyara.com Source – PRNewsWire

Press Release

RedHill Biopharma Announces Presentation of Positive Oral Opaganib Phase 2 Data in COVID-19

Published

on

RedHill Biopharma logo

Positive U.S. Phase 2 safety and efficacy data for opaganib, a leading novel, oral, dual-mechanism drug candidate for moderate-to-severe COVID-19, presented at the World Microbe Forum

Opaganib was associated with a reduction in the need for supplemental oxygen support, earlier time to discharge from hospital and was well tolerated

Opaganib’s global 475-patient Phase 2/3 study is fully enrolled, with study completion expected in the coming weeks

Opaganib is host-targeted and expected to be effective against emerging viral variants

TEL AVIV, Israel and RALEIGH, NC, June 21, 2021 /PRNewswire/ — RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced presentation of the positive Phase 2 safety and efficacy data for oral opaganib (Yeliva®, ABC294640)[1] in hospitalized patients with COVID-19 pneumonia at the World Microbe Forum (WMF) 2021 (poster #: 5574).

RedHill Biopharma logo

Results and post hoc analyses of data from the 40-patient U.S. Phase 2 study were presented in a poster entitled, “Opaganib, an Oral Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia: A Randomized, Double-blind, Placebo-controlled Phase 2A Study, in Adult Subjects Hospitalized with SARS-CoV-2 Positive Pneumonia (NCT: 04414618)“[2]. Patients in the study were randomized to receive either opaganib or placebo in addition to standard of care (SoC), predominantly including dexamethasone and/or remdesivir. Findings include:

  • 50% of patients treated with opaganib (n=22) reached room air by Day 14 compared to 22% in the placebo group (n=18). The benefit of reaching room air by Day 14 for patients on opaganib was maintained regardless of whether the patients were receiving dexamethasone and/or remdesivir
  • 86.4% of patients treated with opaganib were discharged from hospital by Day 14 compared to 55.6% of patients treated with placebo
  • Median time to discharge was 6 days for the opaganib group compared to 7.5 days for the placebo group
  • 81.8% of opaganib patients achieved a 2-point improvement in the WHO Ordinal Scale compared to 55.6% of patients in the placebo group – achieved in a median time of 6 days versus 7.5 days, respectively
  • No significant differences in safety-related measures between the two groups (with diarrhea being the main treatment-emergent difference in tolerability)

“The need for an effective oral therapy to treat COVID-19 is clear. Such a therapy would greatly improve our ability to manage this pandemic,” said Kevin Winthrop, MD, MPH, Professor of Infectious Diseases at Oregon Health & Science University, who presented the findings at WMF. “These data, from this proof-of-concept clinical study of opaganib in patients with severe COVID-19, suggest a potential role of SK2 inhibition in combating the effects of this virus. With much more data on opaganib expected in the coming weeks, we could make some real progress toward having access to a much-needed oral therapy for patients who currently have a paucity of options available to them.”

“Presentation of these positive data from our exploratory Phase 2 study support our growing confidence that opaganib could be the first novel, oral therapy to demonstrate efficacy in the treatment of COVID-19 in a large late-stage study. With the recent completion of enrollment of our 475-patient global Phase 2/3 study, we will have a clearer picture of that in the very near future,” said Mark L. Levitt, MD, Ph.D., Medical Director at RedHill. “Opaganib acts on both the cause and effect of COVID-19 via a unique dual antiviral and anti-inflammatory mode of action. Being host-targeted, opaganib is also expected to maintain effect against the emerging SARS-CoV-2 variants, which continue to threaten the progress being made against the pandemic and underscore the urgent need for effective COVID-19 therapeutics.”

The global 475-patient Phase 2/3 study of opaganib in severe COVID-19 has been approved in 10 countries and completed enrollment, through 57 participating sites, on June 6th. The primary endpoint of the study is the proportion of patients breathing room air without oxygen support by Day 14. Additional important outcome measures, such as time to discharge from hospital, improvement according to the World Health Organization Ordinal Scale for Clinical Improvement and incidence of intubation and mortality, will also be captured in the follow-up period of up to 6 weeks. The study received four independent DSMB recommendations to continue following unblinded safety reviews and a futility review. Additionally, an evaluation of the blinded blended intubation and mortality rates to date was encouraging as compared to reported rates of mortality from large platform studies such as RECOVERY, and other studies in similar patient populations[3].

About Opaganib (Yeliva®, ABC294640)

Opaganib, a new chemical entity, is a proprietary, first-in-class, orally-administered, sphingosine kinase-2 (SK2) selective inhibitor, with dual anti-inflammatory and antiviral activity, that is host-targeted and is therefore expected to be effective against emerging viral variants. Opaganib has also shown anticancer activity and has the potential to target multiple oncology, viral, inflammatory, and gastrointestinal indications.

Opaganib is being evaluated as a treatment for COVID-19 pneumonia in a global Phase 2/3 study, which recently completed enrollment, and has demonstrated positive safety and efficacy signals in preliminary top-line data from the 40-patient U.S. Phase 2 study.

Opaganib has also received Orphan Drug designation from the U.S. FDA for the treatment of cholangiocarcinoma and is being evaluated in a Phase 2a study in advanced cholangiocarcinoma and in a Phase 2 study in prostate cancer.

Opaganib demonstrated potent antiviral activity against SARS-CoV-2, the virus that causes COVID-19, completely inhibiting viral replication in an in vitro model of human lung bronchial tissue. Additionally, preclinical in vivo studies have demonstrated opaganib’s potential to ameliorate inflammatory lung disorders, such as pneumonia, and has shown decreased fatality rates from influenza virus infection and ameliorated Pseudomonas aeruginosa-induced lung injury by reducing the levels of IL-6 and TNF-alpha in bronchoalveolar lavage fluids[4].

The ongoing studies with opaganib are registered on www.ClinicalTrials.gov, a web-based service by the U.S. National Institute of Health, which provides public access to information on publicly and privately supported clinical studies.   

About RedHill Biopharma    

RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs, Movantik® for opioid-induced constipation in adults[5], Talicia® for the treatment of Helicobacter pylori (H. pylori) infection in adults[6], and Aemcolo® for the treatment of travelers’ diarrhea in adults[7]. RedHill’s key clinical late-stage development programs include: (i) RHB-204, with an ongoing Phase 3 study for pulmonary nontuberculous mycobacteria (NTM) disease; (ii) opaganib (Yeliva®, ABC294640), a firstinclass SK2 selective inhibitor targeting multiple indications with positive Phase 2 COVID-19 data and an ongoing Phase 2/3 program for COVID-19 and Phase 2 studies for prostate cancer and cholangiocarcinoma ongoing; (iii) RHB-107 (upamostat), a serine protease inhibitor in a U.S. Phase 2/3 study as treatment for symptomatic COVID-19, and targeting multiple other cancer and inflammatory gastrointestinal diseases; (iv) RHB-104, with positive results from a first Phase 3 study for Crohn’s disease; (v) RHB-102 (Bekinda®), with positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D; and (vi) RHB106, an encapsulated bowel preparation. More information about the Company is available at www.redhillbio.com / https://twitter.com/RedHillBio.         

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include the delay in last patient visit and top-line data from the Phase 2/3 COVID-19 study for opaganib, that the Phase 2/3 COVID-19 study for opaganib may not be successful and, even if successful, such study and results may not be sufficient for regulatory applications, including emergency use or marketing applications, and that additional COVID-19 studies for opaganib are likely to be required by regulatory authorities to support such potential applications and the use or marketing of opaganib for COVID-19 patients, that opaganib will not be effective against emerging viral variants, as well as risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company’s research, manufacturing, preclinical studies, clinical trials, and other therapeutic candidate development efforts, and the timing of the commercial launch of its commercial products and ones it may acquire or develop in the future; (ii) the Company’s ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials (iii) the extent and number and type of additional studies that the Company may be required to conduct and the Company’s receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company’s therapeutic candidates and Talicia®; (v) the Company’s ability to successfully commercialize and promote Movantik®, Talicia® and Aemcolo®; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) the Company’s ability to acquire products approved for marketing in the U.S. that achieve commercial success and build and sustain its own marketing and commercialization capabilities; (viii) the interpretation of the properties and characteristics of the Company’s therapeutic candidates and the results obtained with its therapeutic candidates in research, preclinical studies or clinical trials; (ix) the implementation of the Company’s business model, strategic plans for its business and therapeutic candidates; (x) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and commercial products and its ability to operate its business without infringing the intellectual property rights of others; (xi) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (xii) estimates of the Company’s expenses, future revenues, capital requirements and needs for additional financing; (xiii) the effect of patients suffering adverse events using investigative drugs under the Company’s Expanded Access Program; and (xiv) competition from other companies and technologies within the Company’s industry. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 20-F filed with the SEC on March 18, 2021. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement, whether as a result of new information, future events or otherwise unless required by law.

 

Company contact:

Adi Frish

Chief Corporate & Business Development Officer

RedHill Biopharma

+972-54-6543-112

adi@redhillbio.com

Media contacts:

U.S.: Bryan Gibbs, Finn Partners

+1 212 529 2236

bryan.gibbs@finnpartners.com

UK: Amber Fennell, Consilium

+44 (0) 7739 658 783  

fennell@consilium-comms.com

 

[1] Opaganib is an investigational new drug, not available for commercial distribution.

[2] Opaganib, an Oral Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia: A Randomized, Double-blind, Placebo-controlled Phase 2A Study, in Adult Subjects Hospitalized with SARS-CoV-2 Positive Pneumonia (NCT: 04414618). K. L. Winthrop, A. W. Skolnick, A. M. Rafiq, S. H. Beegle, J. Suszanski, G. Koehne, O.Barnett-Griness, A. Bibliowicz, R. Fathi, P. Anderson, G. Raday, G. Eagle, V. Katz Ben-Yair, H. S. Minkowitz, M. L. Levitt, M. S. Gordon

[3] Based on preliminary blinded blended data from 463 patients. The Company did not conduct a head-to-head comparison study in the same patient population. The theoretical comparison between the global Phase 2/3 study with opaganib and reported rates of mortality from large platform studies such as RECOVERY, and other studies in similar patient populations, serves as a general benchmark and should not be construed as a direct and/or applicable comparison as if the Company conducted a head-to-head comparison study.

[4] Xia C. et al. Transient inhibition of sphingosine kinases confers protection to influenza A virus infected mice. Antiviral Res. 2018 Oct; 158:171-177. Ebenezer DL et al. Pseudomonas aeruginosa stimulates nuclear sphingosine-1-phosphate generation and epigenetic regulation of lung inflammatory injury. Thorax. 2019 Jun;74(6):579-591.

[5] Full prescribing information for Movantik® (naloxegol) is available at: www.Movantik.com.  

[6] Full prescribing information for Talicia® (omeprazole magnesium, amoxicillin and rifabutin) is available at: www.Talicia.com.       

[7] Full prescribing information for Aemcolo® (rifamycin) is available at: www.Aemcolo.com.

Logo – https://mma.prnewswire.com/media/1334141/RedHill_Biopharma_Logo.jpg

 

 

Continue Reading

Press Release

Pandora Boosts Online Sales by Transforming Its Global Omnichannel e-Commerce with IBM Sterling Supply Chain Software

Published

on

Pandora, a leading designer, manufacturer and marketer of hand-finished jewelry, is using IBM Sterling Order Management for improved real-time inventory visibility. Photo courtesy Pandora.

One of the world’s largest jewelry brands by volume uses IBM Sterling Order Management on Cloud to revamp its fulfillment capabilities and customer experience

ARMONK, N.Y., June 21, 2021 /PRNewswire/ — IBM (NYSE: IBM) has worked with Pandora (NASDAQ: PNDORA), a leading designer, manufacturer and marketer of hand-finished jewelry, to help Pandora transform and scale its global omnichannel e-commerce capabilities with IBM Sterling Order Management. Pandora, one of the world’s largest jewelry brands, was able to double its online sales in 2020 and is now leading the jewelry industry with improved real-time inventory visibility to better manage growing demand.

Pandora, a leading designer, manufacturer and marketer of hand-finished jewelry, is using IBM Sterling Order Management for improved real-time inventory visibility. Photo courtesy Pandora.

Pandora’s focus on innovating new customer experiences included using IBM Sterling Order Management to help to increase the company’s supply chain resiliency and business agility, and better mitigate disruptions and risk. By automating more of their order orchestration across channels, they also have opportunity to improve the sustainability and resiliency of their supply chain operations with more efficient delivery.

“Over the past couple of years, Pandora has made significant investments in digital capabilities and data, and we have consolidated, simplified and modernized the technology stack to bring digital and store technology closer together and closer to the customer,” said Jim Cruickshank, VP of Digital Development & Retail Technology, Pandora. “Our mission is about creating a personal experience and we’ve instituted massive platform changes with IBM Sterling and Salesforce to enable new digital-first capabilities that are much more individualized, localized and connected across channels and markets.”

Pandora’s entry into e-commerce over the last six years most recently led them to consolidate legacy technologies while deploying the new order management solution across its key markets. Using IBM Sterling Order Management as its backend for omnichannel fulfillment and Salesforce Commerce Cloud for e-commerce, Pandora created a seamless shopping experience across channels. By automating order orchestration processes, store associates and virtual customer service representatives are able to have an end-to-end view across inventory, order and delivery status to help meet consumer expectations.

To support this ambitious objective, Pandora established a Digital Hub in Copenhagen, Denmark, with dedicated digital, data and tech teams that have played a vital role in the solution’s quick deployment entirely remotely. As the pandemic forced Pandora to temporarily close most of its 2,700 stores, the digital investments in supply chain efficiency helped fuel the company’s e-commerce success. In addition to some of the go-to fulfillment options many retailers offered such as buy online pickup in store (BOPIS) and endless aisle, Pandora also introduced more innovative approaches such as virtual queuing for stores and AR-based virtual trials of products to help drive more immersive customer engagement.

“The global disruption every industry experienced as all forms of commerce were severely impacted by the pandemic was especially challenging for organizations with disconnected distributed order management systems and limited scalability,” said Jordan Speer, Research Manager – Global Supply Chain, IDC Retail Insights. “This vulnerability created a push to more quickly advance technology adoption that helps retailers better respond to fluctuating consumer dynamics. To meet this changing demand, enterprises are looking to harness new tools to achieve increased levels of supply chain resilience and efficiency while also allowing for more virtual interactions.”

Pandora’s detailed view on order and order lines as well as near real-time inventory management helped to improve insights throughout their systems chain spanning warehouse management solutions, e-commerce and customer contact center. This was further enabled with increased automation from self-service capabilities and the use of chatbots aiding customer support functions as Pandora experienced a massive increase in order volumes.

“The lifeblood of the global economy, consumer behavior, has significantly shifted and will continue to evolve with businesses needing to quickly adapt to new preferences and needs. To address this shift, leading retailers like Pandora rely on innovation to increase their business agility by enabling and scaling sustainable supply chain operations using AI and cloud,” said Kareem Yusuf, General Manager, AI Applications and Blockchain, IBM. “Pandora’s experience shows that they can stay competitive as business and technology leaders are finding new ways to create differentiated customer experiences that protect their enterprises from disruptions to help mitigate risk and accelerate growth.”

To hear more about Pandora’s omnichannel experience using IBM Sterling Order Management view their THINK 2021 keynote detailing how they continue to execute on their strategic initiatives by navigating one of the world’s greatest supply chain disruption.

About Pandora

Pandora designs, manufactures and markets hand-finished jewelry made from high-quality materials at affordable prices. Pandora jewellery is sold in more than 100 countries through more than 6,700 points of sale, including around 2,700 concept stores.

Headquartered in Copenhagen, Denmark, Pandora employs 26,000 people worldwide and crafts its jewelry at two LEED certified facilities in Thailand using mainly recycled silver and gold. The company plans to be carbon neutral by 2025 and has joined the Science Based Targets initiative to reduce emissions across its full value chain. Pandora is listed on the Nasdaq Copenhagen stock exchange and generated sales of DKK 19.0 billion (EUR 2.5 billion) in 2020.

About IBM Sterling Supply Chain

IBM Sterling Supply Chain solutions empower IT and supply chain professionals with greater visibility, transparency and trust to proactively predict and mitigate disruption, improve B2B information flow, and optimize inventory utilization and fulfillment. Learn how our AI- and blockchain-enabled solutions help you build an intelligent, self-correcting supply chain at www.ibm.com/supply-chain.

Contacts:

Heli Koenkyto

Heli.Koenkyto@ibm.com

Erik Mason

erik.mason@ibm.com

IBM Corporation logo.

Photo – https://mma.prnewswire.com/media/1536971/IBM_Sterling_Pandora_mobile.jpg

Logo – https://mma.prnewswire.com/media/95470/ibm_logo.jpg

Continue Reading

Press Release

Xinhua Silk Road: 2021 World Industrial and Energy Internet Expo & International Industrial Equipment Exhibition held on Fri. in E. China's Changzhou

Published

on

Photo: The 2021 World Industrial and Energy Internet Expo and International Industrial Equipment Exhibition kicks off on Friday, in Changzhou, east China's Jiangsu Province.

BEIJING, June 21, 2021 /PRNewswire/ — The 2021 World Industrial and Energy Internet Expo and International Industrial Equipment Exhibition kicked off on Friday, in Changzhou, east China’s Jiangsu Province.

Photo: The 2021 World Industrial and Energy Internet Expo and International Industrial Equipment Exhibition kicks off on Friday, in Changzhou, east China's Jiangsu Province.

Hundreds of experts, scholars and industry elites actively participated in the event to discuss together hot topics such as industrial Internet, energy Internet, smart manufacturing, big data, etc., and share their cutting-edge views and experiences with an aim to inject new impetus into the country’s low-carbon manufacturing industry.

It is learned that agreements on 20 key projects were signed at this year’s expo with a total investment of 30 billion yuan.

Those projects cover fields such as high-end equipment manufacturing, power batteries, 5G communications, photovoltaic new energy, industrial Internet, etc.

The event has been held for three consecutive years since 2019 and achieved remarkable results. 

It is learned that as the only exhibition in Jiangsu that takes the industrial Internet as the local strength and characteristic industry, the expo adheres to the digital transformation of the service industry. The expo has intensively displayed a batch of the latest technologies and achievements in the fields of industrial and energy Internet and high-end equipment manufacturing sectors, accelerated the gathering of various high-end factors such as industry technology, talents, project industries, etc., and played a positive role in the development of the industrial Internet in Jiangsu and even the whole country.

At present, Changzhou is steering towards its positioning of “international intelligent manufacturing city and the central axis hub of the Yangtze River Delta “, firmly grasping the trend of the industrial Internet, vigorously developing intelligent manufacturing and smart energy, and constantly polishing the golden sign of Changzhou’s intelligent manufacturing.

Original link: https://en.imsilkroad.com/p/322222.html

Photo – https://mma.prnewswire.com/media/1537420/2021_World_Industrial_and_Energy_Internet_Expo.jpg  

Continue Reading

Trending